SCHEMBL5648307

SCHEMBL5648307

Cc1ccc(S(=O)(=O)N2CCc3ccc(OC(=O)N(C)c4ccccc4)cc3C2C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
AKR1C3 P42330 1/20 0.48
TAS2R14 Q9NYV8 2/20 0.48
ACHE P22303 3/20 0.47
MMP1 P03956 3/20 0.46
MMP2 P08253 2/20 0.46
MMP7 P09237 2/20 0.46
MMP9 P14780 2/20 0.46
MMP12 P39900 2/20 0.46
MMP14 P50281 2/20 0.46
MMP15 P51511 2/20 0.46
MMP16 P51512 2/20 0.46
MMP26 Q9NRE1 2/20 0.46
ALDH1A1 P00352 4/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
RECQL P46063 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647156 0.89 AKR1C3 (0.45) KMT2AMEN1AKR1C3TAS2R14ACHE
SCHEMBL5651380 0.81 AKR1C3 (0.54) KMT2AMEN1AKR1C3ALDH1A1HTT
SCHEMBL5652554 0.70 MEN1 (0.52) KMT2AMEN1AKR1C3MAPTSMN1; SMN2
SCHEMBL25270458 0.70 SMN1; SMN2 (0.71) KMT2AMEN1ALDH1A1MAPTLMNA
SCHEMBL5648369 0.68 HTR6 (0.41) KMT2AMEN1AKR1C3TAS2R14MMP1
SCHEMBL5650744 0.68 HRH3 (0.62) AKR1C3ALDH1A1LMNAPOLB
SCHEMBL5645854 0.67 FFAR1 (0.61) KMT2AMEN1ALDH1A1MAPTLMNA
SCHEMBL5648897 0.66 SMN1; SMN2 (0.64) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL3392249 0.65 MMP1 (0.61) KMT2AMEN1MMP1MMP2MMP7
SCHEMBL3392244 0.65 MMP1 (0.61) KMT2AMEN1MMP1MMP2MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL KMT2A 4150/4885MEN1 2277/4885AKR1C3 1902/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL KMT2A 4322/4885MEN1 1767/4885AKR1C3 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.